However, with regard to certain biomarkers relevant for pediatric brain tumors (e.g., MYCC and MYCN amplification, β-catenin testing), the prognostic value has not yet been sufficiently clarified because of the rarity of these tumors. The gene discussed is MYC; the disease is brain neoplasm.